{
    "info": {
        "nct_id": "NCT06384807",
        "official_title": "A Phase 1/2, First in Human, Dose Escalation and Dose Expansion Study of BHV-1510 (Previously PBI-410) as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumors",
        "inclusion_criteria": "* Male or female participants aged ≥18 years.\n* Unresectable, incurable, locally advanced or metastatic epithelial-origin solid tumor that is refractory to standard therapies, or has no approved standard therapies, or no approved standard therapies at its current treatment stage. If applicable to the tumor type, participants must have received platinum-based chemotherapy, standard of care immunotherapy, and standard of care targeted therapies.\n* Measurable disease (per RECIST 1.1).\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.\n* Participants have adequate hematologic, renal, liver, and coagulation function as defined by the following (blood transfusion or growth factor support is not allowed within 7 days prior to blood samples that will be used to establish eligibility):\n\n  * Hemoglobin ≥9 g/dL\n  * Absolute neutrophil count >1,500/mm3\n  * Platelets >100,000/mm3\n  * Creatinine clearance ≥50 mL/min measured or estimated using the Cockcroft-Gault formula; 24-hour urine collection is allowed, but not required.\n  * Total bilirubin ≤1.5 × upper limit of normal (ULN); participants with known Gilbert's syndrome who have total bilirubin level ≤3×ULN may be enrolled.\n  * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <2.5×ULN (or ≤5×ULN for participants with hepatic metastases)\n  * Alkaline phosphatase <2.5×ULN (or ≤5×ULN for participants with hepatic and/or bone metastases)\n  * International normalized ratio (INR) or prothrombin time (PT) ≤1.5×ULN\n  * Activated partial thromboplastin time (aPTT) ≤1.5×ULN. Study participants on therapeutic doses of anticoagulation medication must have INR and/or aPTT ≤ the upper limit of the therapeutic range for intended use\n* Have recovered (ie, improvement to Grade 1 or better) from all acute toxicities from previous therapy, excluding alopecia and vitiligo.\n\nBHV-1510 in Combination with specific inclusion criteria:\n\n* histologically or cytologically documented advanced (locally, recurrent, inoperable, cannot be treated with curative intent) or metastatic cancer.\n* received ≤ 2 prior lines of systemic anti-cancer therapy and at most one prior anti-programmed cell death protein 1 (PD-1) (programmed death-ligand 1 [PD-L1]) therapy for advanced/ metastatic disease.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Women who are pregnant or lactating.\n* Clinically significant intercurrent disease.\n* Has symptomatic brain metastases or has had any radiation or surgery for brain metastases within 4 weeks of C1D1.\n* Has clinically significant corneal disease.\n* Requires supplemental oxygen for daily activities.\n* Previous treatment with a Trop-2-targeted therapy, including Trop-2 ADCs.\n* Has a medical history of interstitial lung disease (eg, noninfectious interstitial pneumonia requiring steroid treatment, pneumonitis, pulmonary fibrosis, or severe radiation pneumonitis) or current interstitial lung disease or are suspected to have any of these diseases based on imaging at Screening.\n* Any standard cancer therapy (eg, chemotherapy, hormonal therapy, radiotherapy, immunotherapy, biologic therapy treatment) or experimental therapy within 3 weeks or 5 half-lives, whichever is shorter, prior to C1D1. The interval may be reduced to 2 weeks for bone-only radiation therapy. Any major surgical procedure within 6 weeks prior to C1D1.\n* History of severe hypersensitivity reactions to other monoclonal antibodies or either the drug substances or inactive ingredients of BHV-1510.\n* History of interstitial lung disease (eg, noninfectious interstitial pneumonia requiring steroid treatment, pneumonitis, pulmonary fibrosis, or severe radiation pneumonitis) or current interstitial lung disease or are suspected to have any of these diseases based on most recent imaging.\n\nBHV-1510 in Combination Specific Exclusion Criteria:\n\n* Hypersensitivity to cemiplimab or any of its excipients or contraindicated to cemiplimab per approved local labeling.\n* Experienced Grade 3 or higher immune-related AEs with prior treatment of anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).\n* Prior allogeneic stem cell or solid organ transplantation.\n* Patients with history of myocarditis.",
        "miscellaneous_criteria": "Key"
    },
    "inclusion_lines": [
        {
            "line": "* Measurable disease (per RECIST 1.1).",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease (per RECIST 1.1)",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_criteria",
                            "expected_value": "RECIST 1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine clearance ≥50 mL/min measured or estimated using the Cockcroft-Gault formula; 24-hour urine collection is allowed, but not required.",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance ≥50 mL/min measured or estimated using the Cockcroft-Gault formula",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "mL/min"
                            }
                        },
                        {
                            "requirement_type": "measurement method",
                            "expected_value": [
                                "measured",
                                "estimated using the Cockcroft-Gault formula"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "24-hour urine collection is allowed, but not required",
                    "criterion": "24-hour urine collection",
                    "requirements": [
                        {
                            "requirement_type": "allowed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "required",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Key",
            "criterions": [
                {
                    "exact_snippets": "Key",
                    "criterion": "key eligibility criteria",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "N/A"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin ≥9 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin ≥9 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male or female participants aged ≥18 years.",
            "criterions": [
                {
                    "exact_snippets": "Male or female participants",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "aged ≥18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum_age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin ≤1.5 × upper limit of normal (ULN); participants with known Gilbert's syndrome who have total bilirubin level ≤3×ULN may be enrolled.",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin ≤1.5 × upper limit of normal (ULN)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "participants with known Gilbert's syndrome who have total bilirubin level ≤3×ULN may be enrolled",
                    "criterion": "total bilirubin in participants with known Gilbert's syndrome",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants have adequate hematologic, renal, liver, and coagulation function as defined by the following (blood transfusion or growth factor support is not allowed within 7 days prior to blood samples that will be used to establish eligibility):",
            "criterions": [
                {
                    "exact_snippets": "adequate hematologic ... function",
                    "criterion": "hematologic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "adequate ... renal ... function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "adequate ... liver ... function",
                    "criterion": "liver function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "adequate ... coagulation function",
                    "criterion": "coagulation function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "blood transfusion or growth factor support is not allowed within 7 days prior to blood samples that will be used to establish eligibility",
                    "criterion": "blood transfusion or growth factor support",
                    "requirements": [
                        {
                            "requirement_type": "use within 7 days prior to blood samples for eligibility",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Activated partial thromboplastin time (aPTT) ≤1.5×ULN. Study participants on therapeutic doses of anticoagulation medication must have INR and/or aPTT ≤ the upper limit of the therapeutic range for intended use",
            "criterions": [
                {
                    "exact_snippets": "Activated partial thromboplastin time (aPTT) ≤1.5×ULN",
                    "criterion": "activated partial thromboplastin time (aPTT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Study participants on therapeutic doses of anticoagulation medication must have INR and/or aPTT ≤ the upper limit of the therapeutic range for intended use",
                    "criterion": "INR (international normalized ratio)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": "≤ the upper limit of the therapeutic range for intended use"
                        }
                    ]
                },
                {
                    "exact_snippets": "Study participants on therapeutic doses of anticoagulation medication must have INR and/or aPTT ≤ the upper limit of the therapeutic range for intended use",
                    "criterion": "activated partial thromboplastin time (aPTT) (for participants on anticoagulation)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": "≤ the upper limit of the therapeutic range for intended use"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* received ≤ 2 prior lines of systemic anti-cancer therapy and at most one prior anti-programmed cell death protein 1 (PD-1) (programmed death-ligand 1 [PD-L1]) therapy for advanced/ metastatic disease.",
            "criterions": [
                {
                    "exact_snippets": "received ≤ 2 prior lines of systemic anti-cancer therapy",
                    "criterion": "prior lines of systemic anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "lines"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "at most one prior anti-programmed cell death protein 1 (PD-1) (programmed death-ligand 1 [PD-L1]) therapy for advanced/ metastatic disease",
                    "criterion": "prior anti-PD-1/PD-L1 therapy for advanced/metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "therapy"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1",
                    "criterion": "ECOG Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unresectable, incurable, locally advanced or metastatic epithelial-origin solid tumor that is refractory to standard therapies, or has no approved standard therapies, or no approved standard therapies at its current treatment stage. If applicable to the tumor type, participants must have received platinum-based chemotherapy, standard of care immunotherapy, and standard of care targeted therapies.",
            "criterions": [
                {
                    "exact_snippets": "Unresectable",
                    "criterion": "tumor resectability",
                    "requirements": [
                        {
                            "requirement_type": "resectability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "incurable",
                    "criterion": "tumor curability",
                    "requirements": [
                        {
                            "requirement_type": "curability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "locally advanced or metastatic",
                    "criterion": "tumor stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "epithelial-origin solid tumor",
                    "criterion": "tumor histology",
                    "requirements": [
                        {
                            "requirement_type": "origin",
                            "expected_value": "epithelial"
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": "solid tumor"
                        }
                    ]
                },
                {
                    "exact_snippets": "refractory to standard therapies",
                    "criterion": "response to standard therapies",
                    "requirements": [
                        {
                            "requirement_type": "refractory",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "no approved standard therapies",
                    "criterion": "availability of approved standard therapies",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "no approved standard therapies at its current treatment stage",
                    "criterion": "availability of approved standard therapies at current treatment stage",
                    "requirements": [
                        {
                            "requirement_type": "availability at current stage",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "participants must have received platinum-based chemotherapy",
                    "criterion": "prior platinum-based chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "received",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "participants must have received ... standard of care immunotherapy",
                    "criterion": "prior standard of care immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "received",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "participants must have received ... standard of care targeted therapies",
                    "criterion": "prior standard of care targeted therapies",
                    "requirements": [
                        {
                            "requirement_type": "received",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count >1,500/mm3",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count >1,500/mm3",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1500,
                                "unit": "mm3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* histologically or cytologically documented advanced (locally, recurrent, inoperable, cannot be treated with curative intent) or metastatic cancer.",
            "criterions": [
                {
                    "exact_snippets": "histologically or cytologically documented",
                    "criterion": "cancer diagnosis documentation",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "histological",
                                "cytological"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "advanced (locally, recurrent, inoperable, cannot be treated with curative intent) or metastatic cancer",
                    "criterion": "cancer stage/status",
                    "requirements": [
                        {
                            "requirement_type": "stage/status",
                            "expected_value": [
                                "advanced (locally)",
                                "recurrent",
                                "inoperable",
                                "cannot be treated with curative intent",
                                "metastatic"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* International normalized ratio (INR) or prothrombin time (PT) ≤1.5×ULN",
            "criterions": [
                {
                    "exact_snippets": "International normalized ratio (INR) ... ≤1.5×ULN",
                    "criterion": "international normalized ratio (INR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "prothrombin time (PT) ≤1.5×ULN",
                    "criterion": "prothrombin time (PT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "BHV-1510 in Combination with specific inclusion criteria:",
            "criterions": [
                {
                    "exact_snippets": "BHV-1510 in Combination",
                    "criterion": "BHV-1510 combination therapy",
                    "requirements": [
                        {
                            "requirement_type": "planned treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "specific inclusion criteria",
                    "criterion": "other specific inclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "fulfillment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Alkaline phosphatase <2.5×ULN (or ≤5×ULN for participants with hepatic and/or bone metastases)",
            "criterions": [
                {
                    "exact_snippets": "Alkaline phosphatase <2.5×ULN",
                    "criterion": "alkaline phosphatase",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Alkaline phosphatase ... ≤5×ULN for participants with hepatic and/or bone metastases",
                    "criterion": "alkaline phosphatase in participants with hepatic and/or bone metastases",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have recovered (ie, improvement to Grade 1 or better) from all acute toxicities from previous therapy, excluding alopecia and vitiligo.",
            "criterions": [
                {
                    "exact_snippets": "Have recovered (ie, improvement to Grade 1 or better) from all acute toxicities from previous therapy",
                    "criterion": "acute toxicities from previous therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "CTCAE grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "excluding alopecia and vitiligo",
                    "criterion": "alopecia",
                    "requirements": [
                        {
                            "requirement_type": "exclusion from recovery requirement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "excluding alopecia and vitiligo",
                    "criterion": "vitiligo",
                    "requirements": [
                        {
                            "requirement_type": "exclusion from recovery requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets >100,000/mm3",
            "criterions": [
                {
                    "exact_snippets": "Platelets >100,000/mm3",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 100000,
                                "unit": "mm3"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Experienced Grade 3 or higher immune-related AEs with prior treatment of anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).",
            "criterions": [
                {
                    "exact_snippets": "Experienced Grade 3 or higher immune-related AEs with prior treatment of anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137)",
                    "criterion": "immune-related adverse events (AEs)",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "Grade"
                            }
                        },
                        {
                            "requirement_type": "temporal relationship",
                            "expected_value": "with prior treatment of anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hypersensitivity to cemiplimab or any of its excipients or contraindicated to cemiplimab per approved local labeling.",
            "criterions": [
                {
                    "exact_snippets": "Hypersensitivity to cemiplimab or any of its excipients",
                    "criterion": "hypersensitivity to cemiplimab or its excipients",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "contraindicated to cemiplimab per approved local labeling",
                    "criterion": "contraindication to cemiplimab",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Requires supplemental oxygen for daily activities.",
            "criterions": [
                {
                    "exact_snippets": "Requires supplemental oxygen for daily activities.",
                    "criterion": "supplemental oxygen requirement",
                    "requirements": [
                        {
                            "requirement_type": "necessity for daily activities",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previous treatment with a Trop-2-targeted therapy, including Trop-2 ADCs.",
            "criterions": [
                {
                    "exact_snippets": "Previous treatment with a Trop-2-targeted therapy, including Trop-2 ADCs.",
                    "criterion": "previous treatment with Trop-2-targeted therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Previous treatment with ... Trop-2 ADCs.",
                    "criterion": "previous treatment with Trop-2 ADCs",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any standard cancer therapy (eg, chemotherapy, hormonal therapy, radiotherapy, immunotherapy, biologic therapy treatment) or experimental therapy within 3 weeks or 5 half-lives, whichever is shorter, prior to C1D1. The interval may be reduced to 2 weeks for bone-only radiation therapy. Any major surgical procedure within 6 weeks prior to C1D1.",
            "criterions": [
                {
                    "exact_snippets": "Any standard cancer therapy (eg, chemotherapy, hormonal therapy, radiotherapy, immunotherapy, biologic therapy treatment) or experimental therapy within 3 weeks or 5 half-lives, whichever is shorter, prior to C1D1.",
                    "criterion": "prior cancer therapy or experimental therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "5 half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "The interval may be reduced to 2 weeks for bone-only radiation therapy.",
                    "criterion": "prior bone-only radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Any major surgical procedure within 6 weeks prior to C1D1.",
                    "criterion": "prior major surgical procedure",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of interstitial lung disease (eg, noninfectious interstitial pneumonia requiring steroid treatment, pneumonitis, pulmonary fibrosis, or severe radiation pneumonitis) or current interstitial lung disease or are suspected to have any of these diseases based on most recent imaging.",
            "criterions": [
                {
                    "exact_snippets": "History of interstitial lung disease",
                    "criterion": "interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "noninfectious interstitial pneumonia requiring steroid treatment",
                    "criterion": "noninfectious interstitial pneumonia",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "steroid treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "pneumonitis",
                    "criterion": "pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "pulmonary fibrosis",
                    "criterion": "pulmonary fibrosis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "severe radiation pneumonitis",
                    "criterion": "severe radiation pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "current interstitial lung disease",
                    "criterion": "interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "current",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "suspected to have any of these diseases based on most recent imaging",
                    "criterion": "interstitial lung disease or related conditions (noninfectious interstitial pneumonia, pneumonitis, pulmonary fibrosis, severe radiation pneumonitis)",
                    "requirements": [
                        {
                            "requirement_type": "suspected based on imaging",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women who are pregnant or lactating.",
            "criterions": [
                {
                    "exact_snippets": "Women who are pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "lactating",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a medical history of interstitial lung disease (eg, noninfectious interstitial pneumonia requiring steroid treatment, pneumonitis, pulmonary fibrosis, or severe radiation pneumonitis) or current interstitial lung disease or are suspected to have any of these diseases based on imaging at Screening.",
            "criterions": [
                {
                    "exact_snippets": "Has a medical history of interstitial lung disease (eg, noninfectious interstitial pneumonia requiring steroid treatment, pneumonitis, pulmonary fibrosis, or severe radiation pneumonitis)",
                    "criterion": "interstitial lung disease (including noninfectious interstitial pneumonia requiring steroid treatment, pneumonitis, pulmonary fibrosis, severe radiation pneumonitis)",
                    "requirements": [
                        {
                            "requirement_type": "medical history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "current interstitial lung disease",
                    "criterion": "interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "current diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "suspected to have any of these diseases based on imaging at Screening",
                    "criterion": "interstitial lung disease (including noninfectious interstitial pneumonia, pneumonitis, pulmonary fibrosis, severe radiation pneumonitis)",
                    "requirements": [
                        {
                            "requirement_type": "suspected diagnosis based on imaging at Screening",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with history of myocarditis.",
            "criterions": [
                {
                    "exact_snippets": "Patients with history of myocarditis",
                    "criterion": "myocarditis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically significant intercurrent disease.",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant intercurrent disease",
                    "criterion": "intercurrent disease",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has clinically significant corneal disease.",
            "criterions": [
                {
                    "exact_snippets": "clinically significant corneal disease",
                    "criterion": "corneal disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "clinically significant"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of severe hypersensitivity reactions to other monoclonal antibodies or either the drug substances or inactive ingredients of BHV-1510.",
            "criterions": [
                {
                    "exact_snippets": "History of severe hypersensitivity reactions to other monoclonal antibodies",
                    "criterion": "hypersensitivity reactions to other monoclonal antibodies",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "History of severe hypersensitivity reactions to ... either the drug substances ... of BHV-1510",
                    "criterion": "hypersensitivity reactions to drug substances of BHV-1510",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "History of severe hypersensitivity reactions to ... inactive ingredients of BHV-1510",
                    "criterion": "hypersensitivity reactions to inactive ingredients of BHV-1510",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has symptomatic brain metastases or has had any radiation or surgery for brain metastases within 4 weeks of C1D1.",
            "criterions": [
                {
                    "exact_snippets": "Has symptomatic brain metastases",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has had any radiation or surgery for brain metastases within 4 weeks of C1D1",
                    "criterion": "radiation or surgery for brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "reference timepoint",
                            "expected_value": "C1D1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior allogeneic stem cell or solid organ transplantation.",
            "criterions": [
                {
                    "exact_snippets": "Prior allogeneic stem cell or solid organ transplantation.",
                    "criterion": "history of transplantation",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "allogeneic stem cell",
                                "solid organ"
                            ]
                        },
                        {
                            "requirement_type": "prior",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [
        {
            "line": "Key",
            "criterions": [
                {
                    "exact_snippets": "Key",
                    "criterion": "key eligibility criteria",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "N/A"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_inclusion": [
        {
            "line": "* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <2.5×ULN (or ≤5×ULN for participants with hepatic metastases)",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) <2.5×ULN (or ≤5×ULN for participants with hepatic metastases)",
                    "criterion": "aspartate aminotransferase (AST)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 2.5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT) <2.5×ULN (or ≤5×ULN for participants with hepatic metastases)",
                    "criterion": "alanine aminotransferase (ALT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 2.5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) ... ≤5×ULN for participants with hepatic metastases",
                    "criterion": "aspartate aminotransferase (AST) in participants with hepatic metastases",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT) ... ≤5×ULN for participants with hepatic metastases",
                    "criterion": "alanine aminotransferase (ALT) in participants with hepatic metastases",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [
        {
            "line": "BHV-1510 in Combination Specific Exclusion Criteria:",
            "criterions": []
        }
    ],
    "failed_miscellaneous": []
}